Chaim Sheba Medical Center ( Site 0076)

Ramat Gan, Tel Aviv 5265601

0 studies enrolling now · 1 studies all time

What they study most

Head and Neck Squamous Cell Carcinoma (HNSCC)

Studies at this site

• Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002) — Completed